RecruitingPhase 4NCT07141004

A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis

Sponsor

Johnson & Johnson Private Limited

Enrollment

100 participants

Start Date

Aug 12, 2025

Study Type

INTERVENTIONAL

Conditions

Arthritis, Psoriatic

Summary

The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Guselkumab for people with arthritis, psoriatic. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGuselkumab

Guselkumab will be administered as subcutaneous injection.

Locations(10)

Cims Hospital

Ahmedabad, India

Post Graduate Institute of Medical Education And Research PGIMER

Chandigarh, India

Chennai Meenakshi Multispeciality Hospital

Chennai, India

All India Institute of Medical Sciences 1

Gorakhpur, India

Nizams Institute of Medical Sciences

Hyderabad, India

P. D. Hinduja National Hospital and Research Center

Mumbai, India

All India Institute of Medical Sciences

New Delhi, India

Sir Ganga Ram Hospital

New Delhi, India

All India Institute of Medical Sciences

Patna, India

Jehangir Clinical Development Centre

Pune, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07141004

Related Trials

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089139 locations

A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting

NCT0722082421 locations

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424224 locations

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT0666333247 locations

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT0732187372 locations